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Introduction
Prostate cancer is the most prevalent cancer in men in Western societies (1). Although the majority of prostate cancers behave in an indolent manner, a small subset is highly aggressive and requires extensive treatment (2, 3) . Established prognostic parameters are limited to Gleason grade and tumor extent on biopsies, preoperative prostate-specific antigen (PSA) and clinical stage.
Because these data are statistically powerful, but often insufficient for optimal individual treatment decisions, it is hoped that a better understanding of disease biology will eventually lead to the identification of clinically applicable molecular markers that enable a more reliable prediction of prostate cancer aggressiveness. FOXA1 (Fork-head box protein A1, HNF-3a) is a chromatin binding pioneer factor involved in epigenetic transcription control (4) . FOXA1 governs expression programs related to growth and differentiation in many different organs, including liver, kidney, lung, pancreas, brain, mammary gland and prostate (5) (6) (7) . In breast and prostate glands, FOXA1 enables nuclear hormone receptors including estrogen receptor (ER) and androgen receptor (AR) to access their target gene promoters (8) (9) (10) . Several studies have linked altered FOXA1 function to cancer development and progression. For example, increased FOXA1 expression has been linked to poor prognosis in lung cancer (11) , thyroid cancer (12) and gliomas (13) , but to good prognosis in bladder (14) , endometrial (15) and breast cancer (16) (17) (18) , suggesting that the prognostic role of FOXA1 may depend on the specific cancer type. In prostate cancer, the prognostic role of FOXA1 expression levels remains controversial (19) . Some studies on 102-350 prostate cancers suggest a link between FOXA1 overexpression and unfavourable prognosis (20, 21) , while other studies reported loss or inactivating mutations of FOXA1 in castration-resistant, high-grade prostate cancers (22, 23) . Given the potential relevance of FOXA1 expression in prostate cancer, we investigated this protein on our pre-existing prostate cancer tissue microarray (TMA) containing 11 152 prostate cancer specimens including various molecularly defined subgroups. The results of this study show that high FOXA1 expression is strongly linked to early PSA recurrence in ETS-related gene (ERG) negative but not in ERG positive prostate cancers.
Materials and methods

Patients
Radical prostatectomy specimens were evaluable from 11 152 patients, undergoing surgery between 1992 and 2011 at the Department of Urology and the Martini Clinics at the University Medical Center HamburgEppendorf. Follow-up data were available for a total of 7652 patients with a median follow-up of 58.2 months (range: 1 to 264 months; Table 1 ). Histopathological data were retrieved from the patients' records, including tumor stage, Gleason grade, nodal stage and stage of the resection margin. In addition to the classical Gleason categories, "quantitative" Gleason grading was performed as described before (24) . In brief, for every prostatectomy specimen, the percentages of Gleason 3, 4 and 5 patterns were recorded in cancerous tissues as part of the regular process of Gleason grading. Gleason 3 + 4 and 4 + 3 cancers were subdivided according to their percentage of Gleason 4. For practical use, we subdivided the 3 + 4 and 4 + 3 cancers in eight subgroups: 3 + 4 ≤5% Gleason 4, 3 + 4 6-10%, 3 + 4 11-20%, 3 + 4 21-30%, 3 + 4 31-49%, 4 + 3 50-60%, 4 + 3 61-80% and 4 + 3 >80% Gleason 4. In addition, separate groups were defined by the presence of a tertiary Gleason 5 pattern, including 3 + 4 Tertiary 5 and 4 + 3 Tertiary 5. PSA values were measured following surgery and PSA recurrence was defined as a post-operative PSA of 0.2 ng/ml and increasing at subsequent measurements. All prostate specimens were analyzed according to a standard procedure, including a complete embedding of the entire prostate for histological analysis (25) . The TMA manufacturing process was described earlier in detail (26) . In short, one 0.6 mm core was taken from a representative tissue block from each patient. The tissues were distributed among 24 TMA blocks, each containing 144 to 522 tumor samples. For internal controls, each TMA block also contained various control tissues, including normal prostate tissue. The molecular database attached to this TMA contained results on ERG expression in 9618, ERG break apart by fluorescence in-situ hybridization (FISH) analysis in 6106 (expanded from (27) ) and deletion status of 5q21 (CHD1) in 7230 (expanded from (28)), 6q15 (MAP3K7) in 5542 (29) , PTEN (10q23) in 6115 (expanded from (30) ) and 3p13 (FOXP1) in 6444 cancers. The utilization of tissues and clinical data was according to the Hamburgisches Krankenhausgesetz ( §12 HmbKHG). Informed consent was not necessary. The study was approved by the Ärztekammer Hamburg (WF-049/09).
Immunohistochemistry
Freshly cut TMA sections were stained on 1 day and in one experiment. Primary antibody specific for FOXA1 (goat, ab5089, Abcam, Cambridge, UK; dilution 1:300) was applied, slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7.8 Tris-EDTA-Citrate buffer. Bound antibody was then visualized using the EnVision Kit (Dako, Glostrup, Denmark). Staining controls included tissues with known FOXA1 expression (normal prostate epithelium). As FOXA1 staining intensity was found to be highly homogeneous within individual tissue spots, the evaluation included staining intensity as the sole parameter. For each tissue spot, one pathologist classified the staining intensity as negative, weak, moderate or strong.
Statistics
Statistical calculations were performed with JPM 9 software (SAS Institute Inc., NC). Contingency tables and the chi 2 -test were performed to search for associations between molecular parameters and tumor phenotype. Survival curves were calculated according to Kaplan-Meier. The Log-Rank test was applied to detect significant survival differences between groups. Cox proportional hazards regression analysis was performed to test the statistical independence and significance between pathological, molecular and clinical variables. Separate analyses were performed using different sets of parameters available either before or after prostatectomy.
Results
Technical issues
A total of 8227 (73.8%) of tumor samples were interpretable in our TMA analysis. Reasons for non-informative cases (2925 spots; 26.2%) included lack of tissue samples or absence of unequivocal cancer tissue in the TMA spot.
FOXA1 expression in prostate cancer
FOXA1 staining was predominantly localized in the nucleus and frequently accompanied by cytoplasmic staining of comparable intensity. In some rare cases, staining was limited to the cytoplasm. FOXA1 expression often showed little differences between invasive prostate cancers and adjacent normal prostate tissue. Positive FOXA1 staining was seen in 8028 of our 8227 (97.6%) interpretable prostate cancers and was considered weak in 22.9%, moderate in 46.2% and strong in 28.5% of cancers (Table 2 ). Representative images of positive and negative FOXA1 staining are given in Figure 1 .
Association with TMPRSS2:ERG fusion status
Among patients with interpretable FOXA1 staining, data on TMPRSS2:ERG fusion status obtained by FISH were available from 4864 patients and by IHC from 7551 patients. High-level FOXA1 staining was tightly linked to TMPRSS2:ERG rearrangement and ERG expression in prostate cancers (P < 0.0001 each; Figure 2 ). 
Abbreviations
Association with tumor phenotype
Increased FOXA1 expression was significantly linked to high Gleason grade and advanced pathological tumor (pT) stage if all tumors were jointly analyzed (P < 0.0001 each, Table 2 ). Subgroup analyses of ERG positive and ERG negative cancers revealed that these associations were largely driven by ERG negative cancers (P < 0.0001 each, Supplementary Table S1 is available at Carcinogenesis Online), and were much less evident in ERG positive cancers (Supplementary Table S2 is available at Carcinogenesis Online).
Association to other key genomic deletions
A comparison of FOXA1 expression with deletions of PTEN (10q23), 3p13 (FOXP1), 6q15 (MAP3K7) and 5q21 (CHD1) deletions revealed that PTEN and 5q21 deletions were significantly linked to high FOXA1 expression (P < 0.0001 each; Supplementary Figure S1 is available at Carcinogenesis Online). Separate analyses of ERG positive and ERG negative cancers showed that these associations were especially evident in ERG negative cancers (P < 0.0001) while they largely disappeared in ERG positive cancers (P = 0.0278 for PTEN, P = 0.8497 for 5q21).
Association with PSA recurrence
Follow-up data were available for 10 376 patients with interpretable FOXA1 staining on the TMA. The prognostic impact of traditional and quantitative Gleason grade is shown in Figure 3a and b. High FOXA1 expression was strongly associated with early PSA recurrence if all tumors were jointly analyzed (P < 0.0001; Figure 3c ). Because of the small number of entirely negative cancers and their similar clinical behavior as seen for cancers with weak FOXA1 expression, these two groups were subsequently combined as "low" expressers for further analyses (Figure 3d ). Subgroup analysis of ERG positive and ERG negative cancers revealed that the association between high FOXA1 expression and PSA recurrence was to a large extent driven by ERG negative cancers (P < 0.0001; Figure 3e ) while the prognostic impact of FOXA1 expression vanished in ERG positive cancers (P = 0.0253; Figure 3f ). 
Multivariate analysis
Multivariate analyses evaluate the clinical relevance of FOXA1 expression in different scenarios (Table 3) . Scenario 1 includes all preoperatively available parameters (preoperative Gleason grade obtained at biopsy, clinical tumor stage (cT) and preoperative PSA) and the post-operative FOXA1 expression level. In scenario 2, the biopsy Gleason is replaced by the Gleason grade obtained at radical prostatectomy. In scenario 3, cT-stage is superseded by pT stage and surgical margin (R) status. Scenario 4 adds the lymph node (pN) stage. These analyses revealed that-in ERG negative cancers-high-level FOXA1 expression is a strong independent prognostic feature in all scenarios ( Table 3 ). The prognostic role of FOXA1 expression was strong enough that high-level FOXA1 remained an independent predictor of poor prognosis in unselected prostate cancers in most scenarios, even though FOXA1 expression lacked prognostic importance in ERG positive cancer.
Discussion
The results of our study identify FOXA1 expression levels as a strong prognostic feature in prostate cancer and demonstrate that this prognostic impact is strictly limited to the subgroup of ERG negative tumors. In this study, immunohistochemical analyses revealed positive FOXA1 staining in 97.6% of prostate cancers, which is in accordance with earlier studies reporting expression rates of 62-100% (20, (31) (32) (33) 102-529 patients. The extensive molecular database attached to our TMA allowed us to draw some conclusions on the consequences of FOXA1 expression in prostate cancer. About half of prostate cancers carry gene fusions linking the androgen-regulated serine protease TMPRSS2 with the transcription factor ERG (34). As a result of this rearrangement, the expression of ERG becomes androgen regulated and massively overexpressed. Our data demonstrate markedly higher FOXA1 expression levels in ERG positive than in ERG negative cancers. Finding this association by two independent approaches for ERG fusion detection (IHC/FISH) largely excludes a false positive association, caused by non-functional tissue. There are several possible (19) . Third, it could be speculated that substantially higher levels of FOXA1 expression are required in ERG positive than in ERG negative cancers because the transcription factors ERG and FOXA1 could compete for a common set of downstream target genes. Finally, it appears possible that ERG expression could disrupt FOXA1 signaling as it has been shown for AR signaling before (37) . In such a scenario, elevated FOXA1 levels might represent a compensatory up regulation in order to maintain sufficient FOXA1 activity in the presence of ERG. Our data further demonstrate that FOXA1 does not only exhibit different expression levels in ERG positive and ERG negative cancers but also exerts an entirely different biological impact in these groups. Associations of FOXA1 expression with unfavourable tumor phenotype and with PSA recurrence were entirely driven by ERG negative cancers, while the impact of FOXA1 expression on tumor phenotype and PSA recurrence was almost absent in ERG positive cancers. Studies have demonstrated that ERG activation results in a modified expression level of hundreds of genes in prostate epithelial cells (23, 38, 39) . Our data seem to suggest that ERG-induced dysregulation of various pathways either directly or indirectly affects FOXA1 and that this interaction leads to an attenuation of those FOXA1 functions that are related to cancer cell aggressiveness. The strong link between high FOXA1 expression and PTEN deletions suggests a functional relationship between FOXA1 expression and disruptions of the PI3K/AKT pathway. Interactions with this pathway are indeed known to exist for FOXA1 (12, 32) as well as other FOX protein family members (40, 41) . For example, FOXA1 increases AR signaling capacity and triggers cell growth while FOXO1 and FOXO3 have antagonistic functions and are downstream effectors of the PTEN tumor suppressor (42) . Although the exact molecular mechanisms of FOX proteins and PTEN deletion remain unclear, it seems likely that concurrent FOXA1 activation and putative FOXO-factor inactivation by PTEN loss may synergistically drive tumor progression. Irrespective of the mechanisms connected with FOX factor alterations, our data identify FOXA1 as an independent and thus potentially clinically useful prognostic feature in prostate cancer. It is of note that the use of prostatectomy samples for the analysis of prognostic features has obvious limitations as the natural history of these tumors is at least in many cases interrupted by potentially curative surgery. Prostatectomy tissues are the only realistically available tissue sources for such studies, however. Molecular features can hardly be analyzed on preoperative biopsies because these are typically distributed among many different sites where the initial diagnosis was made and even if these biopsies were available for analyses such precious collections of tissues would be used up after only a few studies. To compensate as much as possible for the disadvantage of using prostatectomy specimens for this project, several models for multivariate analyses were used. These were designed to-as close as possible-model the application of prognostic features in pre-and post-operative scenarios. All these models revealed a strong and independent prognostic impact of FOXA1 expression in the subgroup of ERG negative cancers. Finding such subtype-specific prognostic features challenges the concept of molecular classifiers that apply to all prostate cancers. Several multiparametric prognostic tests were recently suggested in prostate cancer (43) (44) (45) (46) and some of them are now commercially available (47, 48) . It will be interesting to see, how these tests perform in molecularly defined prostate cancer subgroups. Based Gleason grading but also demonstrates how difficult it is for biomarkers to outperform optimized morphological malignancy parameters in prostate cancer. Nevertheless, it is our anticipation that prognostic gene sets will assist routine clinical decision-making in prostate cancer in the future. It appears likely that combining molecular markers will enable a better and reproducible prognosis prediction than analyzing single markers. In summary, our study identified a strong link of high FOXA1 expression with early PSA recurrence in ERG negative prostate cancers, which was independent of grade, stage, margin status, pN involvement and preoperative PSA level. FOXA1 expression analysis-either alone or in combination with other molecular parameters-might result in clinically useful information in ERG negative cancer.
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